Jade Biosciences reports $35 million quarterly loss

Jade Biosciences (NASDAQ:JBIO) reported a third-quarter 2026 net loss of $35.055 million as it increased spending on clinical development programmes targeting autoimmune diseases.

The loss widened from $25.175 million a year earlier, although loss per common share narrowed to $0.42 from $0.48.

Research and development expenses increased to $30.823 million from $22.010 million, while general and administrative expenses rose to $8.817 million from $5.391 million.

The company expects to initiate JADE101's Phase 3 EVERGREEN trial for immunoglobulin A nephropathy (IgAN) in the fourth quarter of 2026, with interim results from its Phase 2 JUNIPER trial expected in the second quarter of 2027.

Jade also expects JADE201 Phase 1 interim results in rheumatoid arthritis during 2027 and plans to begin JADE301's Phase 1 healthy-volunteer trial in the fourth quarter of 2026, with interim results expected in the second half of 2027.

Cash, cash equivalents and investments totalled $475.706 million at September 30, 2026, and the company expects its funding to support operations into the fourth quarter of 2028 under its current operating plans.